MIR338

Summary

MIR338 (microRNA 338, HGNC:31775) is a microRNA gene on chromosome 17q25.3.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 442906 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31775
Approved symbol	MIR338
Name	microRNA 338
Location	17q25.3
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-338
Ensembl gene	ENSG00000283604
Ensembl biotype	miRNA
OMIM	614059
Entrez	442906
RNAcentral	URS000075E706 — miRNA, 67 nt, 7 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000636369

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000636369 — 1 exons

Exon	Start	End
ENSE00003800127	81125883	81125949

Expression profiles

Bgee: expression breadth broad, 29 present calls, max score 75.02.

Top tissues by expression

29 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 9	UBERON:0013540	75.02	gold quality
gastrocnemius	UBERON:0001388	73.92	gold quality
omental fat pad	UBERON:0010414	72.36	gold quality
blood	UBERON:0000178	70.92	gold quality
heart left ventricle	UBERON:0002084	70.31	gold quality
transverse colon	UBERON:0001157	69.74	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	68.27	gold quality
body of stomach	UBERON:0001161	68.08	gold quality
lower esophagus muscularis layer	UBERON:0035833	66.47	gold quality
skin of abdomen	UBERON:0001416	66.14	gold quality
right hemisphere of cerebellum	UBERON:0014890	65.59	gold quality
cerebellar hemisphere	UBERON:0002245	65.35	gold quality
left lobe of thyroid gland	UBERON:0001120	65.32	gold quality
tibial artery	UBERON:0007610	65.30	gold quality
left adrenal gland cortex	UBERON:0035825	65.03	gold quality
small intestine Peyer’s patch	UBERON:0003454	64.58	gold quality
thoracic mammary gland	UBERON:0005200	64.26	gold quality
skin of leg	UBERON:0001511	64.07	gold quality
tibial nerve	UBERON:0001323	63.80	gold quality
thyroid gland	UBERON:0002046	63.25	gold quality
subcutaneous adipose tissue	UBERON:0002190	63.11	gold quality
pituitary gland	UBERON:0000007	62.33	gold quality
esophagus mucosa	UBERON:0002469	62.27	gold quality
amygdala	UBERON:0001876	61.41	gold quality
hypothalamus	UBERON:0001898	61.37	gold quality
spleen	UBERON:0002106	59.81	gold quality
ovary	UBERON:0000992	59.71	gold quality
left testis	UBERON:0004533	58.69	gold quality
upper lobe of left lung	UBERON:0008952	56.59	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Transcriptional activation of apoptosis-associated tyrosine kinase (AATK), also generates miR-338 from an AATK gene intron that silences a family of mRNAs whose protein products are negative regulators of neuronal differentiation. (PMID:18684991)
• Data show that expression of MIR152, MIR200B, and MIR338 is specifically modulated in neuroblastoma cell lines during differentiation and apoptosis. (PMID:20574809)
• Increased miR-338-3p is associated with sporadic amyotrophic lateral sclerosis. (PMID:22903028)
• miR-338-3p inhibits proliferation by regulating CyclinD1 and HBx down-regulates miR-338-3p in hepatocelullar carcinoma. (PMID:22942717)
• Downregulation of miR-338-3p is associated with esophageal squamous cell carcinoma. (PMID:23124769)
• The 3’-UTR of Runx2 is significantly suppressed by expression of miR-338-3p. (PMID:23380982)
• miR-338-3p could suppress colorectal carcinoma growth by inhibiting SMO protein expression. (PMID:23599646)
• The triple miRNA classifier of miR-193a-3p, miR-23a and miR-338-5p appears to be a potential blood biomarker for early detection of colorectal cancer (PMID:23758639)
• MiR-338-3p affects the PTEN/Akt pathway by down-regulating PREX2a. (PMID:24140344)
• Results demonstrate that miR-338-3p affects gastric cancer progression through PTEN-AKT signaling by targeting P-Rex2a in gastric cancer cells. (PMID:24375644)
• miR-338 acts as a novel tumor suppressor gene in gastric cancervby targeting NRP1 expression (PMID:24736504)
• miR-338-3p is expressed differentially in CRC and associated with progression and prognosis of colorectal carcinoma. (PMID:24824250)
• High MIRN338 expression is associated with chronic lymphocytic leukemia. (PMID:24916701)
• We detected a specific microRNA disease-related upregulation, miR-338-3p, in blood leukocytes as well in cerebrospinal fluid, serum, and spinal cord from sporadic Amyotrophic Lateral Sclerosis patients. (PMID:25130371)
• Data show that neuropilin1 (NRP1) was identified as a target of microRNA miR-338 in oral squamous cell carcinoma (OSCC) cells and inversely correlated with miR-338 in OSCC tissues. (PMID:25204970)
• Ectopic miR338-3p expression significantly inhibited Rasrelated protein 14 (RAB14) mRNA and protein expression, and reduced luciferase reporter activity containing the RAB14 3’-untranslated region through the first binding site. (PMID:25374067)
• Loss of MiR-338-3p is associated with drug resistance in hepatocarcinoma. (PMID:25531114)
• These findings suggest that miR-338-3p regulates survival of hepatocellular carcinoma cells partially through the downregulation of FOXP4 (PMID:25755720)
• miR-338-3p inhibited the epithelial-mesenchymal progression in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. (PMID:25945841)
• Mineralocorticoid receptor affects HCC development by modulating the miR-338-3p/pyruvate kinase, liver and red blood cells axis with an ability to suppress the Warburg effect (PMID:26082033)
• Circulating miR-15b-5p, miR-338-5p, and miR-764 may be biomarkers for diagnosis of HCC (PMID:26119771)
• Taken together, we found that miR-338-3p directly targeted HIF-1alpha, and we provide insight into Nasopharyngeal cancer initiation and progression, possibly representing a novel therapeutic target. (PMID:26260688)
• preS2 upregulates TAZ expression by repressing miRNA-338-3p. TAZ is necessary for preS2-promoted HCC proliferation and migration. (PMID:26315112)
• miR-338-3p is significantly decreased in gastric cancer, and inhibits cell proliferation, migration and invasion partially via the downregulation of ADAM17. (PMID:26617808)
• miR-338-3p and miR-338-5p were differentially expressed in GBM tissue in comparison to non-tumor brain tissue. Pre-miR-338-5p (but not miR-338-3p overexpression) notably decreased proliferation and caused cell cycle arrest. This was increased by irradiation. Targets of miR-338-5p were Ndfip1, Rheb, and ppp2R5a. (PMID:26692101)
• miR338-3p has anti-proliferative and anti-invasive properties. It affects CXCR4 axis, and its down-regulation is associated with adverse clinical outcomes in prostate cancer patients. (PMID:26907180)
• MACC1 was a specific target gene of miR-338-3p, which regulates malignant biological behaviors of glioma cells partly through directly silencing MACC1 expression. (PMID:26936749)
• A new regulatory mechanism of miR-338. (PMID:27431198)
• MiR-338-3p was significantly reduced in NSCLC cell lines. Forced expression of miR-338-3p in A549 cells led to the suppression of migration/invasion capacity and inhibition of epithelial markers. (PMID:27453416)
• miR-338-3p can contribute to hepatocellular carcinoma angiogenesis by targeting MACC1, beta-catenin and VEGF signaling pathway. (PMID:27694002)
• miR-338-3p levels were significantly decreased in the thalamus but not the auditory cortex of patients with schizophrenia as compared to those in age- and sex-matched controls. miR-338-3p was enriched in the medial geniculate nucleus as compared to the auditory cortex. (PMID:27892953)
• MiR-338-5p suppressed proliferation, migration and invasion of glioblastoma cells through inhibiting EFEMP1. (PMID:28292024)
• These data identify miR-338-3p as a clinically relevant tumor suppressor in glioblastoma. (PMID:28493990)
• MiR-338-3p suppresses the TNF-alpha-induced lipogenesis in sebocytes by targeting PREX2a and down-regulating PI3K/AKT signaling. (PMID:28597147)
• The expression of miRNA-338 is higher in the supernatant of COPD, asthma, and asthma-COPD overlap syndrome phenotype than in peripheral blood. (PMID:28694694)
• MiR-338-3p represses EYA2 expression by targeting its 3’-3’ Untranslated Region and inhibition of mir-338-3p by mimics significantly decreased the incidence of breast cancer metastasis to the lung. (PMID:28703807)
• that miR-338-5p has a function in promoting glioma cell invasion by targeting TSHZ3 suppression on MMP2 (PMID:28780604)
• We have shown that inhibition of miR-338-3p inhibits secretion of growth hormone and prolactin, as well as cell proliferation (PMID:28808880)
• Increased miR-338-5p significantly inhibited the cell proliferation, cell invasion and epithelial-mesenchymal transition (EMT) in vitro for glioma. (PMID:28826173)
• By inhibiting ADAMTS-9, miR-338-5p suppressed the proliferation and metastasis of rheumatoid arthritis synovial fibroblasts. (PMID:28850027)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.